Skip to main content
    R

    Revvity Inc. (RVTY)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE

    $148.87
    -5.52 (-3.58%)

    Market Cap: $17.24B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Revvity Inc. (RVTY) Earnings: Report Dates and Results

    Updated Nov 3, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Revvity (RVTY) is expected to report earnings on Feb 1, 2027. In the quarter ended Sep 30, 2026, Revvity reported EPS of $1.38, above the $1.29 estimate. It beat the EPS estimate in each of the last 12 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    85%(34/40)
    Avg Surprise
    +9.64%
    Streak
    12 Q

    Upcoming Estimates

    Reports Feb 1, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$1.65
    Range$1.56 - $1.88
    20 analysts
    Revenue Consensus
    $776.24M
    Range$732.35M - $843.24M
    20 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$1.26
    Range$1.14 - $1.41
    10 analysts
    EPS Revisions
    2
    5
    30d
    EPS Estimate DriftChange to current
    90d ago$1.27-0.8%
    60d ago$1.27-0.8%
    30d ago$1.25+0.4%
    7d ago$1.26-0.0%
    Current$1.26
    Revenue Consensus
    $723.86M
    Range$710.28M - $733.99M
    8 analysts

    Next Report

    RVTY has an expected report date of Feb 1, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 2.9% below the $1.70 reported for the quarter ended Dec 31, 2025.

    RVTY Earnings Call

    The latest RVTY earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, RVTY beat 34, missed 4 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $728.90M, up 4.3% from $698.95M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$1.38$1.29$1.28 - $1.33+6.98%Beat+16.9%162 up, 0 downNov 3, 2026$728.90M
    Jun 30, 2026$1.41$1.23$1.18 - $1.28+14.63%Beat+19.5%121 up, 2 downJul 27, 2026$729.69M
    Mar 31, 2026$1.06$1.01$1.00 - $1.03+4.95%Beat+5.0%152 up, 2 downMay 5, 2026$711.12M
    Dec 31, 2025$1.70$1.58$1.53 - $1.64+7.59%Beat+19.7%152 up, 1 downFeb 2, 2026$772.06M
    Sep 30, 2025$1.18$1.14$1.12 - $1.16+3.51%Beat-7.8%162 up, 0 downOct 27, 2025$698.95M
    Jun 30, 2025$1.18$1.14$1.13 - $1.15+3.51%Beat-3.3%173 up, 1 downJul 28, 2025$720.28M
    Mar 31, 2025$1.01$0.95$0.93 - $0.97+6.32%Beat+3.1%180 up, 2 downApr 28, 2025$664.76M
    Dec 31, 2024$1.42$1.38$1.37 - $1.39+2.90%Beat+13.6%131 up, 1 downJan 31, 2025$729.37M
    Sep 30, 2024$1.28$1.13$1.12 - $1.15+13.27%Beat+8.5%181 up, 0 downNov 4, 2024$684.05M
    Jun 30, 2024$1.22$1.12$1.09 - $1.18+8.93%Beat+0.8%170 up, 0 downJul 29, 2024$691.68M
    Mar 31, 2024$0.98$0.94$0.90 - $0.98+4.26%Beat-3.0%151 up, 0 downApr 29, 2024$649.92M
    Dec 31, 2023$1.25$1.16$1.14 - $1.20+7.76%Beat-26.5%166 up, 0 downFeb 1, 2024$1.37B
    Sep 30, 2023$1.18$1.19$1.15 - $1.25-0.84%Miss-21.9%141 up, 3 downOct 30, 2023N/A
    Jun 30, 2023$1.21$1.19$1.15 - $1.20+1.68%Beat-47.8%151 up, 0 downAug 1, 2023$709.07M
    Mar 31, 2023$1.01$1.02N/A-0.98%Miss-58.1%N/AN/AMay 11, 2023$674.87M
    Dec 31, 2022$1.70$1.66N/A+2.41%Beat-33.6%N/AN/AFeb 14, 2023$741.21M
    Sep 30, 2022$1.51$1.48N/A+2.03%Beat-34.6%N/AN/ANov 8, 2022$711.80M
    Jun 30, 2022$2.32$2.01N/A+15.42%Beat-18.0%N/AN/AAug 1, 2022$895.64M
    Mar 31, 2022$2.41$2.12N/A+13.68%Beat-35.2%N/AN/AMay 3, 2022$963.16M
    Dec 31, 2021$2.56$2.35N/A+8.94%Beat-35.4%N/AN/AFeb 1, 2022$430.33M
    Sep 30, 2021$2.31$1.92N/A+20.31%Beat+10.5%N/AN/ANov 2, 2021$861.32M
    Jun 30, 2021$2.83$2.44N/A+15.98%Beat+80.3%N/AN/AJul 26, 2021$1.23B
    Mar 31, 2021$3.72$3.07N/A+21.17%Beat+455.2%N/AN/AMay 4, 2021$1.31B
    Dec 31, 2020$3.96$3.02N/A+31.13%Beat+193.3%N/AN/AFeb 2, 2021$235.09M
    Sep 30, 2020$2.09$1.49N/A+40.27%Beat+97.2%N/AN/AOct 28, 2020$964.02M
    Jun 30, 2020$1.57$0.88N/A+78.41%Beat+57.0%N/AN/AJul 28, 2020$811.72M
    Mar 31, 2020$0.67$0.52N/A+28.85%Beat-2.9%N/AN/AMay 5, 2020$652.40M
    Dec 31, 2019$1.35$1.33N/A+1.50%Beat+14.4%N/AN/AJan 27, 2020$805.50M
    Sep 30, 2019$1.06$1.01N/A+4.95%Beat+17.8%N/AN/AOct 30, 2019$706.92M
    Jun 30, 2019$1.00$1.00N/A0.00%In line+9.9%N/AN/AJul 29, 2019$722.52M
    Mar 31, 2019$0.69$0.66N/A+4.55%Beat+9.5%N/AN/AApr 25, 2019$648.74M
    Dec 31, 2018$1.18$1.16N/A+1.72%Beat+21.6%N/AN/AMar 31, 2019$756.35M
    Sep 30, 2018$0.90$0.92N/A-2.17%Miss+23.3%N/AN/AOct 31, 2018$674.31M
    Jun 30, 2018$0.91$0.86N/A+5.81%Beat+35.8%N/AN/AAug 1, 2018$703.36M
    Mar 31, 2018$0.63$0.61N/A+3.28%Beat+14.5%N/AN/AApr 30, 2018$643.97M
    Dec 31, 2017$0.97$0.94N/A+3.19%Beat+16.9%N/AN/AMar 31, 2018$641.63M
    Sep 30, 2017$0.73$0.72N/A+1.39%Beat+7.4%N/AN/ANov 2, 2017$554.27M
    Jun 30, 2017$0.67$0.67N/A0.00%In line0.0%N/AN/AAug 3, 2017$546.96M
    Mar 31, 2017$0.55$0.54N/A+1.85%Beat-1.8%N/AN/AMay 4, 2017$514.12M
    Dec 31, 2016$0.83$0.86N/A-3.49%Miss-3.5%N/AN/AMar 31, 2017$566.77M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $5.07, up 3.5% from the year before. It was $2.74 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$5.07+3.5%
    Dec 31, 2024$4.90+5.4%
    Dec 31, 2023$4.65-41.4%
    Dec 31, 2022$7.94-30.5%
    Dec 31, 2021$11.42+37.8%
    Dec 31, 2020$8.29+102.2%
    Dec 31, 2019$4.10+13.3%
    Dec 31, 2018$3.62+24.0%
    Dec 31, 2017$2.92+6.6%
    Dec 31, 2016$2.74N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,000 words across 14 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,03914
    2026Q2Jun 30, 20267,74911
    2026Q1Mar 31, 20268,09811
    2025Q4Dec 31, 20259,21614
    2025Q3Sep 30, 20258,74614
    2025Q2Jun 30, 20258,34014
    2025Q1Mar 31, 20259,64113
    2024Q4Dec 31, 20249,22514

    2026Q3 Earnings Call

    Opening remarks

    Stephen Barr Willoughby SVP, Investor Relations Thank you, operator. Good morning, everyone, and welcome to Revvity's Third Quarter 2026 Earnings Conference Call. On the call with me today are Prahlad R. Singh, our President and Chief Executive Officer, and Maxwell Krakowiak, our senior vice president and chief financial officer. Before we begin, I would like to remind you that today's call may include forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from our expectations. Please refer to the Safe Harbor statements in our earnings release and to our SEC filings for a detailed discussion of these risk factors. We assume no obligation to update these forward-looking statements in the future. Additionally, we will refer to certain non-GAAP financial measures during this call. Reconciliations to the most directly comparable GAAP measures are available in our earnings release. I will now turn it over to our President and Chief Executive Officer, Prahlad R. Singh. Prahlad?

    Prahlad R. Singh President and Chief Executive Officer Thank you, Steve, and good morning, everyone. I am pleased to report that Revvity delivered exceptionally strong performance in the third quarter, with pro forma organic growth of 7%, exceeding our mid-single-digit expectation. With healthy gross margins combined with sales leverage from the revenue upside we experienced, our strong incremental margins shone through, leading to pro forma adjusted operating margins in the quarter of 29.4%. This resulted in pro forma adjusted earnings per share of $1.37 for the quarter, which was $0.08 above the midpoint of our expectations. Our stronger-than-expected performance in the quarter was driven by our life sciences segment, which grew 9% organically, with reagents up high single digits, instruments up strong mid-single digits, and our Signals software business growing in the upper teens. This fantastic performance was complemented by solid performance in our diagnostics segment, which grew in the mid-single digits, in line with our expectations. As we have been sharing with you for the last several quarters, underlying market demand trends from our pharma and biotech customers continued to improve in the third quarter, following the policy-related headwinds our industry faced throughout much of last year. On top of this market recovery, we also continued to see incremental AI-related demand build and begin to expand beyond just our high-content screening business, where it was initially concentrated. While our high-content screening revenue growth continued to accelerate in the quarter, despite strong year-ago comps, our backlog for these instruments also continued to increase. We have taken additional actions to further expand our capacity in this area to support this elevated demand, while also building some additional capacity should it accelerate even more as we head into next year.

    Frequently Asked Questions About RVTY

    When is Revvity's next earnings date?

    Revvity's next earnings report is expected for Feb 1, 2027.

    Did RVTY beat earnings estimates last quarter?

    Yes. Revvity reported EPS of $1.38 for the quarter ended Sep 30, 2026, above the $1.29 estimate, a 6.98% surprise.

    What EPS do analysts expect from RVTY next quarter?

    The consensus EPS estimate for Revvity for the quarter ending Dec 31, 2026 is $1.65 from 20 analysts, with estimates from $1.56 to $1.88.

    How often does RVTY beat earnings estimates?

    Revvity beat the EPS estimate in each of the last 12 quarters, with an average surprise of +7.05%.